Clinical Genetic Testing for Fragile X Syndrome by Polymerase Chain Reaction Amplification and Southern Blot Analyses

Area of Science:

• Genetics
• Molecular Biology
• Neurodevelopmental Disorders

Background:

• Fragile X syndrome (FXS) is a leading genetic cause of intellectual disability.
• It results from the expansion of CGG trinucleotide repeats within the 5' untranslated region (UTR) of the FMR1 gene.
• The size and methylation status of these repeats correlate with the clinical presentation of FMR1-related disorders.

Purpose of the Study:

• To outline the genetic basis of Fragile X syndrome.
• To describe the correlation between FMR1 gene alterations and clinical phenotypes.
• To detail the methodologies employed in the clinical genetic testing for FXS.

Main Methods:

• Polymerase chain reaction (PCR) amplification to detect CGG repeat size.
• Southern blot analysis to assess repeat size and methylation status of the FMR1 promoter region.
• Utilizing these methods to identify normal, intermediate, premutation, and full mutation alleles.

Main Results:

• Expansion of CGG trinucleotide repeats in the FMR1 gene is the primary cause of FXS.
• Allele size and FMR1 promoter methylation status are key determinants of the clinical phenotype.
• Established genetic testing methods effectively characterize these repeat expansions and methylation patterns.

Conclusions:

• Clinical genetic testing for FXS relies on PCR and Southern blot analyses.
• These methods accurately detect various CGG repeat sizes and methylation states.
• Understanding repeat characteristics is crucial for diagnosing and managing FMR1-related disorders.